ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 16.52 USD -1.37%
Market Cap: 1.6B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SPRY stock under the Base Case scenario is 27.6 USD. Compared to the current market price of 16.52 USD, ARS Pharmaceuticals Inc is Undervalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SPRY Relative Value
Base Case
27.6 USD
Undervaluation 40%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

16.7
P/S
P/S
Price to Sales
16.7
vs History
42
vs Industry
6
Median 3Y
458.6
Median 5Y
14.3
Industry
7.1
Forward
19
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-18.9
Median 5Y
-18.8
Industry
22.9
Forward
-11
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-17.1
Median 5Y
-16.8
Industry
19.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-14.9
Median 5Y
-14.9
Industry
22.6
More Details
7.1
P/B
P/B
Price to Book Value
7.1
vs History
1
vs Industry
15
Median 3Y
2.9
Median 5Y
2.7
Industry
2.7
More Details
13.9
EV/S
EV/S
Enterprise Value to Sales
13.9
vs History
42
vs Industry
5
Median 3Y
261.2
Median 5Y
10.8
Industry
7.4
Forward
15.8
More Details
14.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
14.2
vs History
5
vs Industry
3
Median 3Y
0
Median 5Y
0
Industry
9.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-10.9
Industry
4.5
Forward
-9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-11.9
Industry
4.5
Forward
-9
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-11.3
Median 5Y
-10.7
Industry
5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-11.3
Median 5Y
-10.7
Industry
3.7
More Details
34.4
EV/IC
EV/IC
Enterprise Value to IC
34.4
vs History
52
vs Industry
0
Median 3Y
43.4
Median 5Y
43.4
Industry
4.9
More Details

Multiples Across Competitors

SPRY Competitors Multiples
ARS Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
ARS Pharmaceuticals Inc
NASDAQ:SPRY
1.6B USD 16.7 -103.6 -50.4 -49.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 710 712 -160 222 -194 560.6 -192 340.5
US
Abbvie Inc
NYSE:ABBV
334.3B USD 5.8 80.5 15.3 22.6
US
Amgen Inc
NASDAQ:AMGN
160.4B USD 4.7 27 14.5 23.9
US
Gilead Sciences Inc
NASDAQ:GILD
139.1B USD 4.8 23.3 10.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.1B USD 10.6 -119.4 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 089.8 -533.3 -580.7 -565.2
AU
CSL Ltd
ASX:CSL
117.5B AUD 5.1 28.1 17.3 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.2B USD 4.2 13.2 11.8 13.2
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -66.6 -60.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
43.3B USD 18.4 -160.4 -720.3 -361
P/E Multiple
Earnings Growth PEG
US
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Average P/E: 34.4
Negative Multiple: -103.6
42%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 222 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
27
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.3
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -119.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -160.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Average EV/EBITDA: 15.7
Negative Multiple: -50.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 560.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -720.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Average EV/EBIT: 20.3
Negative Multiple: -49.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 340.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -361 N/A N/A

See Also

Summary
SPRY intrinsic value, competitors valuation, and company profile.
DCF Valuation
SPRY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SPRY stock valuation using valuation multiples.
Wall Street Estimates
SPRY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SPRY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 265,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.